Introduction
============

Primary congenital aphakia is a rare congenital disorder that has been classified histologically into primary and secondary forms. Primary aphakia appears due to the early developmental arrest of the lens placode leading to the complete absence of the lens, while secondary aphakia is observed in cases where the lens is formed initially but is subsequently resorbed perinatally (OMIM [610256](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=610256)). The phenotypic outcome is quite diverse in these two forms because of the different stages of onset. In primary aphakia, the missing lens formation leads to severe congenital eye malformations, including aplasia of the interior eye segment, whereas secondary aphakia leads to less severe ocular defects.

Primary congenital aphakia is known to be caused by mutations in the forkhead box protein E3 (*FOXE3*) gene in both humans and mice \[[@r1]-[@r6]\]. *FOXE3* is a member of the forkhead family of genes; more than 40 *FOX* genes are known in the human genome and they are transcription factors characterized by an 80--100 amino acid DNA binding forkhead motif. The human *FOXE3* maps to chromosome 1p33, and was initially named *FREAC-8* (forkhead-related activator 8) or *FKHL12* (forkhead, drosophila, homolog-like 12) \[[@r7]\]. The Fox proteins exhibit very high functional diversity, and are involved in very early key developmental processes, including the formation of the notochord and the establishment of the body axis, carnio-pharyngeal development, hair development, hearing, and speech and language \[[@r8]\], and several Fox proteins have been shown to be expressed during eye development \[[@r9]\]. The function of *FOXE3* in lens development has been extensively studied in mice where homozygous null mutations result in congenital aphakia with the absence of lens development \[[@r1],[@r2],[@r10],[@r11]\]. In humans, homozygous *FOXE3* mutations have been associated both with recessive inherited congenital primary aphakia \[[@r3],[@r4]\], and the dominant inheritance of ocular dysgenesis, cataracts and Peters' anomaly \[[@r5],[@r6]\]. Here, we report the characterization of a *FOXE3* mutation identified in a consanguineous Pakistani family that results in primary congenital aphakia.

Methods
=======

Biologic sample
---------------

A large inbred family with congenital primary aphakia was ascertained from a remote village of Pakistan (Basti Moza Kotla Mosa, District Bahawalpur, South Punjab) having many affected individuals. The mode of inheritance as evident from the segregation of disease alleles in the pedigree was autosomal recessive. Venous blood samples were collected from fifteen members of the family, depending on their availability and willingness to participate in the study. Genomic DNA was extracted following the standard phenol:chloroform method.

STS marker analysis
-------------------

All known autosomal recessive cataract loci were enlisted ([Table 1](#t1){ref-type="table"}) and initially screened using two or more STS (Sequence-Tagged-Site) marker systems for each locus in order to exclude the possibility of cataract involvement in the phenotype. A 3-primer STS marker protocol was developed for the fragment analyses using ABI3130*XL* and GeneMapper 3.0 technology (Applied Biosystems, Foster City, CA). The 3-primer labeling system uses a FAM labeled primer (FAM-TGA CCG GCA GCA AAA TT), and the identical primer sequence was added 5′ to one of the genome specific PCR primers. All oligonucleotides were purchased from TAG Copenhagen (Copenhagen, Denmark). Briefly, for the 3-primer protocol, the primer concentrations were: FAM-primer 0.8 μM, forward extended primer 0.1 μM, and reverse primer 0.25 μM applying standard PCR conditions using Ampliqon III Taq polymerase (Ampliqon, Copenhagen, Denmark). The PCR conditions were as follows: pre-denaturation 95 °C, 10 min; then 30 cycles 95 °C, 1 min; 60 °C (or specific annealing temperature tested by temperature gradient), 1 min; 72 °C, 1 min followed by 8 cycles 95 °C, 1 min; 50 °C, 1 min; and 72 °C, 1 min. Total PCR volumes were adjusted to 12 μl using 10--20 ng template DNA. Two point LOD scores were calculated using the LIPED program \[[@r12]\].

###### List of autosomal recessive cataract locus and STS markers.

  **Locus position**   **Markers selected**                              **Gene**          **Ethnicity**              **Reference**
  -------------------- ------------------------------------------------- ----------------- -------------------------- -------------------
  1p34.3-p32.2         D1S255, D1S2892, D1S197                           Unknown           Pakistan                   \[[@r13]\]
  1q21.1               D1S442, D1SGJA5-GJA8\*                            *GJA8* (*CX50*)   South India                \[[@r14]\]
  3p22--24.2           D3S1298                                           Unknown           Arab                       \[[@r15]\]
  6p24.2               D6S470, D6S1034                                   *GCNT2*           Arab                       \[[@r16]\]
  9q13-q22             D9S768, D9S152                                    *CAAR*            Pakistan                   \[[@r17]\]
  14q24.3              D14S986, D14S1025, D14S1047, D14S273              *CHX10*           Turkey, UAE                \[[@r18]\]
  16q22.1              D16S3019, D16S3086, D16S421, D16S3107, D16S3095   *HSF4*            Pakistan, China, Tunisia   \[[@r17],[@r19]\]
  19q13                D19S416                                           Unknown           Pakistan                   \[[@r20]\]
  19q13.33             D19S246                                           *LIM2*            Iraqi Jewish               \[[@r21]\]
  20p12.1              D20S860                                           *BFSP1*           India                      \[[@r22]\]
  22q11.23             D22S421                                           *CRYBB3*                                     \[[@r23]\]
  22q12.1              D22S315, D22S1167                                 *CRYBB1*          Israel                     \[[@r24]\]
  21q22.3              D21S1411, D21S1890, D21S1885                      *CRYAA*           Jewish Persian             \[[@r25]\]

DNA sequencing of *FOXE3*
-------------------------

This gene consists of a single exon and was sequenced for genomic variants by PCR amplification using overlapping sets of primers ([Table 2](#t2){ref-type="table"}) covering the coding region. This was followed by direct DNA sequencing on ABI3130 XL using BigDye ver1.1 technology (Applied Biosystems). The sequences were checked for possible variants using ChromasPro (Technelysium Pty Ltd., Tewantin, Australia) by alignment to the reference sequences (GenBank [NM_012186](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=NM_012186) and [NP_036318](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=NP_036318)). The sequencing primers were purchased from TAG Copenhagen, and the Taq DNA polymerases from Qiagen (Hilden, Germany) and Invitrogen (Carlsbad, CA). The PCR products were analyzed by 2% agarose gel-electrophoresis, 1× TBE and the DNA was stained with ethidium bromide.

###### PCR sequencing primers for *FOXE3*.

  **Forward primer**                  **Reverse primer**                  **PCR length**
  ----------------------------------- ----------------------------------- ----------------
  FOXE3_ex1.1f TGTCCATATAAAGCGGGTCG   FOXE3_ex1.1r ATGTACGAGTAGGGCGGCTT   298 bp
  FOXE3_ex1.2f TTCTCTGGCTTCCCTGCC     FOXE3_ex1.2r TCGGTGATGAAGCGGTAGAT   272 bp
  FOXE3_ex1.3f AAGCCGCCCTACTCGTACAT   FOXE3_ex1.3r TCGTTGAGCGTGAGATTGTG   170 bp
  FOXE3_ex1.4f TTCATCACCGAACGCTTTGC   FOXE3_ex1.4r AGGAAGCTGCCGTTGTCGAA   185 bp
  FOXE3_ex1.5f AAGGGCAACTACTGGACGCT   FOXE3_ex1.5r TAGCTCCGGCTGCAGGTT     267 bp
  FOXE3_ex1.6f TCTGTTCAGCGTCGACAG     FOXE3_ex1.6r CAGGTCGCACAGGTGCC      351 bp

Restriction enzyme digest
-------------------------

The mutation was counter-confirmed using a restriction enzyme digest with DdeI (New England Biolabs, Ipswich, MA) of the PCR product generated by the primer pair FOXE3--1.6 ([Table 2](#t2){ref-type="table"}) under standard conditions in a volume of 20 µl, and the cleaved products were analyzed by 2% agarose gel-electrophoresis, 1× TBE and the DNA was stained with ethidium bromide.

Results and Discussion
======================

All the available DNA samples for family CT1 were genotyped for all possible autosomal recessive cataract loci ([Table 1](#t1){ref-type="table"}) in order to rule out the possibility of cataract involvement in the resulting aphakic eyes. Initial homozygosity was traced on chromosome 1p33 by STS markers D1S255, D1S2892, and D1S197. Haplotype analysis based on more adjacent markers revealed several polymorphisms throughout the family which helped to identify a narrow conserved region around the *FOXE3* gene ([Table 3](#t3){ref-type="table"} and [Figure 1A](#f1){ref-type="fig"}). All the affected individuals presented homozygous alleles except for individuals CT1--7 and CT1--8, whereas the phenotypically normal individuals were either carriers of heterozygous alleles or homozygous. Interestingly, part of the disease haplotype was even brought in from outside the main kindred by CT1--14, suggesting that either the carrier was related to the CT1 family, or that disease carriers are highly prevalent in the region. Individual CT1--14 carried the identical disease haplotype proximal to the *FOXE3* locus but a different haplotype distal to the *FOXE3* locus ([Figure 1A](#f1){ref-type="fig"}), which suggested a recombination between the *FOXE3* locus and the marker D1S2130 (see [Table 3](#t3){ref-type="table"}). LOD score calculations both for the *FOXE3* mutation and the two STS markers ([Table 4](#t4){ref-type="table"}) demonstrated positive LOD scores, with a maximum of Z=6.62 at θ=0.0 for the *FOXE3* mutation.

###### STS markers used for fine mapping of the homozygous region at 1p33.

  **STS marker**   **Physical position chromosome 1 (hg18)**
  ---------------- -------------------------------------------
  D1S496           35,179,917
  D1S2729          36,843,493
  D1S255           37,422,301
  D1S2892          39,963,503
  D1S2130          41,590,073
  FOXE3            47,654,331 - 47,656,311
  D1S2720          47,680,375
  D1S197           50,523,064
  D1S2652          55,239,419
  D1S2890          57,645,988

![Pedigree and haplotype analysis of CT1. **A**: The pedigree of family CT1 shows a high degree of consanguinity in 7 generations. Two haplotypes are represented in the pedigree; the spouse CT1--14 carries the identical mutation and shares the identical haplotype distal to the *FOXE3* gene. The two haplotypes are shown as black or black and gray. Symbols: open circles or squares are healthy individuals, filled symbols represent affected individuals and half filled symbols represent carriers. **B**: Restriction enzyme digests of all the family members where DNA was available demonstrate the segregation of the mutation with the disease in the family. The restriction enzyme DdeI recognizes the mutation and cleaves the 204 bp band into two fragments of 131 bp and 73 bp. An additional 75 bp band is observed in all individuals.](mv-v16-549-f1){#f1}

###### LOD score for *FOXE3* mutations and markers.

  **STS marker**   **θ**                                      
  ---------------- ------- ------ ------ ------ ------ ------ ------
  Order            0.0     0.01   0.05   0.1    0.2    0.3    0.4
  D1S2130          2.40    2.30   2.00   1.70   1.00   0.50   0.10
  c.720C\>A        6.62    6.50   6.00   5.35   3.97   2.51   1.10
  D1S2720          1.60    1.60   1.40   1.10   0.70   0.40   0.10

Mut p=0.001

Sequencing of the coding region of *FOXE3* in one affected individual using overlapping primer pairs ([Table 2](#t2){ref-type="table"}) revealed a C\>A single base substitution (c.720C\>A) leading to a nonsense mutation in the cysteine 240 codon (p.Cys240X) as the underlying genetic cause of the disease phenotype. The restriction enzyme DdeI (recognition site 5′-CTNAG-3′) was chosen to confirm the mutation which cleaves the wild type allele of 204 bp into fragments of 73 bp and 131 bp, respectively. Restriction enzyme cleavage of the family demonstrated segregation of the mutation with the disease trait, and carriers were heterozygote for the wild type and the mutant alleles ([Figure 1B](#f1){ref-type="fig"}) confirming the recessive mode of inheritance adopted by mutation.

The identical mutation was first reported in an inbred family from Madagascar \[[@r3]\]. Presenting the same underlying mutation, both families share the same phenotype showing the complete absence of the lens ([Figure 2](#f2){ref-type="fig"}). Marker analyses were set for one individual from each of the families to see if the shared *FOXE3* mutation originated from the same ancestral founder. No informative SNPs were found in the nearby vicinity of *FOXE3* locus, and so several STS markers in the region were analyzed in one affected person from each family. The haplotype analysis demonstrated different haplotypes segregating in the two families ([Figure 3B](#f3){ref-type="fig"}). As a consequence, it is very likely that the p.C240X mutation occurred independently in the two families.

![The individual CT1--11 showing complete congenital primary aphakia.](mv-v16-549-f2){#f2}

![Genotype analysis of the *FOXE3* mutation. **A**: DNA sequencing chromatograms showing homozygote mutant and carrier status for two individuals. **B**: Microsatellite analysis for one affected form of the Pakistani and Madagascan families demonstrate segregation of different haplotypes in the two families which exclude an ancestral origin for the mutation p.Cys240X. **C**: Schematic presentation of the FOXE3 protein. Recessive inherited mutations (R) and dominant mutations (D) are clearly denoted \[[@r3]-[@r6]\].](mv-v16-549-f3){#f3}

The expression of the *FOXE3* gene is limited to the lens, but mutations in *FOXE3* result in various ocular phenotypes leading either to dominant or recessive inheritance \[[@r3]-[@r6]\]. Mutations in *FOXE3* have been reported in 8 families so far, including CT1 and a total of 7 different mutations have been identified ([Figure 3C](#f3){ref-type="fig"}). Four mutations characterized in families with dominant inheritance are reported in combination with Peters' anomaly, cataract and other ocular dysgenesis \[[@r4]-[@r6]\], and four families, including CT1, manifest recessive inheritance in association with the more severe phenotype primary aphakia \[[@r3],[@r4]\].

All carriers in family CT1 were healthy as reported previously for the three other recessive families \[[@r3],[@r4]\]. This suggests the pathogenic nature to be a null mutation with loss of function rather than haploinsufficiency as suggested earlier \[[@r4],[@r5]\]. Unfortunately, it has not been possible to re-examine the CT1 family after identification of the mutation as a result of escalating security concerns, and internal displacement of the population in the region of Pakistan where the family resides.

*FOXE3* is a single exon gene encoding a 319 amino acid protein, and the recessive p.Cys240X mutation results in premature termination of translation and a truncated protein carrying the forkhead domain ([Figure 3C](#f3){ref-type="fig"}). The very initial expression of *FOXE3* is observed in the lens-forming surface ectoderm (E 9.5), and maintains its presence throughout lens placode formation, and in later processes too as invagination and separation from the ectoderm above. Later during the development, the expression of *FOXE3* is switched off from the differentiating lens fiber cells, restricting itself to the anterior lens epithelium (E 14.5) where its expression remains confined throughout the life of the subject \[[@r2],[@r4]\]. The complete lack of a functional FOXE3 protein product may explain the complete lack of lens development resulting in aphakia observed both in association with the p.Cys240X mutation found in two families as well as for the two other recessive mutations ([Figure 3C](#f3){ref-type="fig"}). Finally, it is noteworthy that all the reported recessive families were consanguineous, and that three out of four were of Pakistani descent.
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